Pharmacological Considerations during Percutaneous Treatment of Heart Failure


Цитировать

Полный текст

Аннотация

Heart Failure (HF) remains a global health challenge, marked by its widespread prevalence and substantial resource utilization. Although the prognosis has improved in recent decades due to the treatments implemented, it continues to generate high morbidity and mortality in the medium to long term. Interventional cardiology has emerged as a crucial player in HF management, offering a diverse array of percutaneous treatments for both acute and chronic HF. This article aimed to provide a comprehensive review of the role of percutaneous interventions in HF patients, with a primary focus on key features, clinical effectiveness, and safety outcomes. Despite the growing utilization of these interventions, there remain critical gaps in the existing body of evidence. Consequently, the need for high-quality randomized clinical trials and extensive international registries is emphasized to shed light on the specific patient populations and clinical scenarios that stand to benefit most from these innovative devices.

Об авторах

Jose Sorolla-Romero

Department of Cardiology, Hospital Universitari i Politècnic La Fe

Email: info@benthamscience.net

Javier Navarrete-Navarro

Department of Cardiology, Hospital Universitari i Politècnic La Fe

Email: info@benthamscience.net

Julia Martinez-Sole

Department of Cardiology, Hospital Universitari i Politècnic La Fe

Email: info@benthamscience.net

Hector Garcia

Department of Cardiology, MedStar Washington Hospital Cente

Email: info@benthamscience.net

Jose Diez-Gil

Department of Cardiology, Hospital Universitari i Politècnic La Fe

Email: info@benthamscience.net

Luis Martinez-Dolz

Department of Cardiology, Hospital Universitari i Politècnic La Fe

Email: info@benthamscience.net

Jorge Sanz-Sanchez

Department of Cardiology, Hospital Universitari i Politècnic La Fe

Автор, ответственный за переписку.
Email: info@benthamscience.net

Список литературы

  1. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42(36): 3599-726. doi: 10.1093/eurheartj/ehab368 PMID: 34447992
  2. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. J Am Coll Cardiol 2022; 79(17): e263-421. doi: 10.1016/j.jacc.2021.12.012 PMID: 35379503
  3. Eltayeb M, Squire I, Sze S. Biomarkers in heart failure: A focus on natriuretic peptides. Heart 2023. doi: 10.1136/heartjnl-2020-318553
  4. Lan T, Liao YH, Zhang J, et al. Mortality and readmission rates after heart failure: A systematic review and meta-analysis. Ther Clin Risk Manag 2021; 17: 1307-20. doi: 10.2147/TCRM.S340587 PMID: 34908840
  5. Taylor CJ, Ordóñez-Mena JM, Roalfe AK, et al. Trends in survival after a diagnosis of heart failure in the United Kingdom 2000-2017: Population based cohort study. BMJ 2019; 364: l223. doi: 10.1136/bmj.l223 PMID: 30760447
  6. Vahdatpour C, Collins D, Goldberg S. Cardiogenic shock. J Am Heart Assoc 2019; 8(8): e011991. doi: 10.1161/JAHA.119.011991 PMID: 30947630
  7. Lee JM, Rhee TM, Hahn JY, et al. Multivessel percutaneous coronary intervention in patients with st-segment elevation myocardial infarction with cardiogenic shock. J Am Coll Cardiol 2018; 71(8): 844-56. doi: 10.1016/j.jacc.2017.12.028 PMID: 29471935
  8. Alba AC, Rao V, Ivanov J, Ross HJ, Delgado DH. Usefulness of the INTERMACS scale to predict outcomes after mechanical assist device implantation. J Heart Lung Transplant 2009; 28(8): 827-33. doi: 10.1016/j.healun.2009.04.033 PMID: 19632580
  9. Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization. J Am Coll Cardiol 2022; 79(2): e21-e129. doi: 10.1016/j.jacc.2021.09.006 PMID: 34895950
  10. Papaioannou TG, Stefanadis C. Basic principles of the intraaortic balloon pump and mechanisms affecting its performance. ASAIO J 2005; 51(3): 296-300. doi: 10.1097/01.MAT.0000159381.97773.9B PMID: 15968962
  11. Thiele H, Zeymer U, Thelemann N, et al. Intraaortic balloon pump in cardiogenic shock complicating acute myocardial infarction. Circulation 2019; 139(3): 395-403. doi: 10.1161/CIRCULATIONAHA.118.038201 PMID: 30586721
  12. Vargas KG, Jäger B, Kaufmann CC, et al. Impella in cardiogenic shock following acute myocardial infarction: A systematic review and meta-analysis. Wien Klin Wochenschr 2020; 132(23-24): 716-25. doi: 10.1007/s00508-020-01712-y PMID: 32691215
  13. Zein R, Patel C, Mercado-Alamo A, Schreiber T, Kaki A. A review of the Impella devices. Interv Cardiol 2022; 17: e05. doi: 10.15420/icr.2021.11 PMID: 35474971
  14. Anderson MB, Goldstein J, Milano C, et al. Benefits of a novel percutaneous ventricular assist device for right heart failure: The prospective RECOVER RIGHT study of the Impella RP device. J Heart Lung Transplant 2015; 34(12): 1549-60. doi: 10.1016/j.healun.2015.08.018 PMID: 26681124
  15. Zein R. A review of the Impella devices 2021. Available from: https://www.icrjournal.com/articles/review-impella-devices
  16. Impella ventricular support systems. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf14/p140003s018d.pdf
  17. Singh V, Yadav PK, Eng MH, et al. Outcomes of hemodynamic support with Impella in very high-risk patients undergoing balloon aortic valvuloplasty: Results from the Global cVAD Registry. Int J Cardiol 2017; 240: 120-5. doi: 10.1016/j.ijcard.2017.03.071 PMID: 28377189
  18. Impella ECP early feasibility study - Full text view. Available from: https://clinicaltrials.gov/ct2/show/NCT04477603
  19. Seyfarth M, Sibbing D, Bauer I, et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol 2008; 52(19): 1584-8. doi: 10.1016/j.jacc.2008.05.065 PMID: 19007597
  20. Ouweneel DM, Eriksen E, Sjauw KD, et al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. J Am Coll Cardiol 2017; 69(3): 278-87. doi: 10.1016/j.jacc.2016.10.022 PMID: 27810347
  21. Schrage B, Ibrahim K, Loehn T, et al. Impella support for acute myocardial infarction complicated by cardiogenic shock. Circulation 2019; 139(10): 1249-58. doi: 10.1161/CIRCULATIONAHA.118.036614 PMID: 30586755
  22. O’Neill WW, Kleiman NS, Moses J, et al. A prospective, randomized clinical trial of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention: The PROTECT II study. Circulation 2012; 126(14): 1717-27. doi: 10.1161/CIRCULATIONAHA.112.098194 PMID: 22935569
  23. Kuchibhotla S, Esposito ML, Breton C, et al. Acute biventricular mechanical circulatory support for cardiogenic shock. J Am Heart Assoc 2017; 6(10): e006670. doi: 10.1161/JAHA.117.006670 PMID: 29054842
  24. Cheung AW, White CW, Davis MK, Freed DH. Short-term mechanical circulatory support for recovery from acute right ventricular failure: Clinical outcomes. J Heart Lung Transplant 2014; 33(8): 794-9. doi: 10.1016/j.healun.2014.02.028 PMID: 24726682
  25. Pivato CA, Ferrante G, Briani M, Sanz Sanchez J, Reimers B, Pagnotta P. Mitraclip treatment for severe mitral regurgitation due to chordae rupture following Impella CP support in a patient with severe aortic stenosis. Cardiovasc Revasc Med 2021; 28: 118-20. doi: 10.1016/j.carrev.2020.08.027 PMID: 32855084
  26. Aragon J, Lee MS, Kar S, Makkar RR. Percutaneous left ventricular assist device: "TandemHeart" for high-risk coronary intervention. Catheter Cardiovasc Interv 2005; 65(3): 346-52. doi: 10.1002/ccd.20339 PMID: 15945107
  27. Burkhoff D, Cohen H, Brunckhorst C, O’Neill WW. A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. Am Heart J 2006; 152(3): 469.e1-8. doi: 10.1016/j.ahj.2006.05.031 PMID: 16923414
  28. Thiele H, Sick P, Boudriot E, et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. Eur Heart J 2005; 26(13): 1276-83. doi: 10.1093/eurheartj/ehi161 PMID: 15734771
  29. Giesler GM, Gomez JS, Letsou G, Vooletich M, Smalling RW. Initial report of percutaneous right ventricular assist for right ventricular shock secondary to right ventricular infarction. Catheter Cardiovasc Interv 2006; 68(2): 263-6. doi: 10.1002/ccd.20846 PMID: 16819772
  30. Takagaki M, Wurzer C, Wade R, et al. Successful conversion of TandemHeart left ventricular assist device to right ventricular assist device after implantation of a HeartMate XVE. Ann Thorac Surg 2008; 86(5): 1677-9. doi: 10.1016/j.athoracsur.2008.04.101 PMID: 19049776
  31. Bajona P, Salizzoni S, Brann SH, et al. Prolonged use of right ventricular assist device for refractory graft failure following orthotopic heart transplantation. J Thorac Cardiovasc Surg 2010; 139(3): e53-4. doi: 10.1016/j.jtcvs.2008.10.042 PMID: 19660327
  32. Rajdev S, Benza R, Misra V. Use of tandem heart as a temporary hemodynamic support option for severe pulmonary artery hypertension complicated by cardiogenic shock. J Invasive Cardiol 2007; 19(8): E226-9. PMID: 17712211
  33. Kapur NK, Esposito ML, Bader Y, et al. Mechanical circulatory support devices for acute right ventricular failure. Circulation 2017; 136(3): 314-26. doi: 10.1161/CIRCULATIONAHA.116.025290 PMID: 28716832
  34. Ravichandran AK, Baran DA, Stelling K, Cowger JA, Salerno CT. Outcomes with the tandem protek duo dual-lumen percutaneous right ventricular assist device. ASAIO J Am Soc Artif Intern Organs 1992 1992; 64(4): 570-2.
  35. Combes A, Price S, Slutsky AS, Brodie D. Temporary circulatory support for cardiogenic shock. Lancet 2020; 396(10245): 199-212. doi: 10.1016/S0140-6736(20)31047-3 PMID: 32682486
  36. Sheu JJ, Tsai TH, Lee FY, et al. Early extracorporeal membrane oxygenator-assisted primary percutaneous coronary intervention improved 30-day clinical outcomes in patients with ST-segment elevation myocardial infarction complicated with profound cardiogenic shock. Crit Care Med 2010; 38(9): 1810-7. doi: 10.1097/CCM.0b013e3181e8acf7 PMID: 20543669
  37. Ouweneel DM, Schotborgh JV, Limpens J, et al. Extracorporeal life support during cardiac arrest and cardiogenic shock: A systematic review and meta-analysis. Intensive Care Med 2016; 42(12): 1922-34. doi: 10.1007/s00134-016-4536-8 PMID: 27647331
  38. Rupprecht L, Lunz D, Philipp A, Lubnow M, Schmid C. Pitfalls in percutaneous ECMO cannulation. Heart Lung Vessel 2015; 7(4): 320-6. PMID: 26811838
  39. Conrad SA, Grier LR, Scott LK, Green R, Jordan M. Percutaneous cannulation for extracorporeal membrane oxygenation by intensivists: A retrospective single-institution case series. Crit Care Med 2015; 43(5): 1010-5. doi: 10.1097/CCM.0000000000000883 PMID: 25746749
  40. Makdisi G, Wang IW. Extra corporeal membrane oxygenation (ECMO) review of a lifesaving technology. J Thorac Dis 2015; 7(7): E166-76. PMID: 26380745
  41. Russo JJ, Aleksova N, Pitcher I, et al. Left ventricular unloading during extracorporeal membrane oxygenation in patients with cardiogenic shock. J Am Coll Cardiol 2019; 73(6): 654-62. doi: 10.1016/j.jacc.2018.10.085 PMID: 30765031
  42. Schrage B, Burkhoff D, Rübsamen N, et al. Unloading of the left ventricle during venoarterial extracorporeal membrane oxygenation therapy in cardiogenic shock. JACC Heart Fail 2018; 6(12): 1035-43. doi: 10.1016/j.jchf.2018.09.009 PMID: 30497643
  43. Cevasco M, Takayama H, Ando M, Garan AR, Naka Y, Takeda K. Left ventricular distension and venting strategies for patients on venoarterial extracorporeal membrane oxygenation. J Thorac Dis 2019; 11(4): 1676-83. doi: 10.21037/jtd.2019.03.29 PMID: 31179113
  44. Pasrija C, Bedeir K, Jeudy J, Kon ZN. Harlequin syndrome during venoarterial extracorporeal membrane oxygenation. Radiol Cardiothorac Imaging 2019; 1(2): e190031. doi: 10.1148/ryct.2019190031 PMID: 33778505
  45. Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail 2020; 22(8): 1342-56. doi: 10.1002/ejhf.1858 PMID: 32483830
  46. van Riet EES, Hoes AW, Limburg A, Landman MAJ, van der Hoeven H, Rutten FH. Prevalence of unrecognized heart failure in older persons with shortness of breath on exertion. Eur J Heart Fail 2014; 16(7): 772-7. doi: 10.1002/ejhf.110 PMID: 24863953
  47. van Riet EES, Hoes AW, Wagenaar KP, Limburg A, Landman MAJ, Rutten FH. Epidemiology of heart failure: The prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. Eur J Heart Fail 2016; 18(3): 242-52. doi: 10.1002/ejhf.483 PMID: 26727047
  48. Stolfo D, Uijl A, Vedin O, et al. Sex-based differences in heart failure across the ejection fraction spectrum. JACC Heart Fail 2019; 7(6): 505-15. doi: 10.1016/j.jchf.2019.03.011 PMID: 31146874
  49. Conrad N, Judge A, Tran J, et al. Temporal trends and patterns in heart failure incidence: A population-based study of 4 million individuals. Lancet 2018; 391(10120): 572-80. doi: 10.1016/S0140-6736(17)32520-5 PMID: 29174292
  50. McDonagh TA, Metra M, Adamo M, et al. 2023 focused update of the 2021 esc guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2023; 44(37): 3627-39. doi: 10.1093/eurheartj/ehad195 PMID: 37622666
  51. Martinez-Sole J, Sanchez-Martinez JC, Lopez-Vilella R, et al. Overview of the treatment of congestion in heart failure. Curr Pharm Des 2023; 29(20): 1592-601. doi: 10.2174/1381612829666230714153404 PMID: 37455461
  52. Goliasch G, Bartko PE, Pavo N, et al. Refining the prognostic impact of functional mitral regurgitation in chronic heart failure. Eur Heart J 2018; 39(1): 39-46. doi: 10.1093/eurheartj/ehx402 PMID: 29020337
  53. Asmarats L, Taramasso M, Rodés-Cabau J. Tricuspid valve disease: Diagnosis, prognosis and management of a rapidly evolving field. Nat Rev Cardiol 2019; 16(9): 538-54. doi: 10.1038/s41569-019-0186-1 PMID: 30988448
  54. Goel SS, Bajaj N, Aggarwal B, et al. Prevalence and outcomes of unoperated patients with severe symptomatic mitral regurgitation and heart failure: Comprehensive analysis to determine the potential role of MitraClip for this unmet need. J Am Coll Cardiol 2014; 63(2): 185-6. doi: 10.1016/j.jacc.2013.08.723 PMID: 24036029
  55. Rossi A, Dini FL, Faggiano P, et al. Independent prognostic value of functional mitral regurgitation in patients with heart failure. A quantitative analysis of 1256 patients with ischaemic and non-ischaemic dilated cardiomyopathy. Heart 2011; 97(20): 1675-80. doi: 10.1136/hrt.2011.225789 PMID: 21807656
  56. Sannino A, Smith RL II, Schiattarella GG, Trimarco B, Esposito G, Grayburn PA. Survival and cardiovascular outcomes of patients with secondary mitral regurgitation. JAMA Cardiol 2017; 2(10): 1130-9. doi: 10.1001/jamacardio.2017.2976 PMID: 28877291
  57. Bursi F, Enriquez-Sarano M, Nkomo VT, et al. Heart failure and death after myocardial infarction in the community: The emerging role of mitral regurgitation. Circulation 2005; 111(3): 295-301. doi: 10.1161/01.CIR.0000151097.30779.04 PMID: 15655133
  58. Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2022; 43(7): 561-632. doi: 10.1093/eurheartj/ehab395 PMID: 34453165
  59. Maisano F, Torracca L, Oppizzi M, et al. The edge-to-edge technique: A simplified method to correct mitral insufficiency1. Eur J Cardiothorac Surg 1998; 13(3): 240-6. doi: 10.1016/S1010-7940(98)00014-1 PMID: 9628372
  60. Feldman T, Foster E, Glower DD, et al. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med 2011; 364(15): 1395-406. doi: 10.1056/NEJMoa1009355 PMID: 21463154
  61. Obadia JF, Messika-Zeitoun D, Leurent G, et al. Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl J Med 2018; 379(24): 2297-306. doi: 10.1056/NEJMoa1805374 PMID: 30145927
  62. Stone GW, Lindenfeld J, Abraham WT, et al. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med 2018; 379(24): 2307-18. doi: 10.1056/NEJMoa1806640 PMID: 30280640
  63. Chehab O, Roberts-Thomson R, Ng Yin Ling C, et al. Secondary mitral regurgitation: Pathophysiology, proportionality and prognosis. Heart 2020; 106(10): 716-23. doi: 10.1136/heartjnl-2019-316238 PMID: 32054671
  64. Stone GW, Abraham WT, Lindenfeld J, et al. Five-year follow-up after transcatheter repair of secondary mitral regurgitation. N Engl J Med 2023; 388(22): 2037-48. doi: 10.1056/NEJMoa2300213 PMID: 36876756
  65. Lim DS, Kar S, Spargias K, et al. Transcatheter valve repair for patients with mitral regurgitation. JACC Cardiovasc Interv 2019; 12(14): 1369-78. doi: 10.1016/j.jcin.2019.04.034 PMID: 31255562
  66. Webb JG, Hensey M, Szerlip M, et al. 1-year outcomes for transcatheter repair in patients with mitral regurgitation from the CLASP study. JACC Cardiovasc Interv 2020; 13(20): 2344-57. doi: 10.1016/j.jcin.2020.06.019 PMID: 33092709
  67. De Backer O, Wong I, Taramasso M, Maisano F, Franzen O, Søndergaard L. Transcatheter mitral valve repair: An overview of current and future devices. Open Heart 2021; 8(1): e001564. doi: 10.1136/openhrt-2020-001564 PMID: 33911022
  68. McInerney A, Marroquin-Donday L, Tirado-Conte G, et al. Transcatheter treatment of mitral regurgitation. J Clin Med 2022; 11(10): 2921. doi: 10.3390/jcm11102921 PMID: 35629048
  69. Yoon SH, Whisenant BK, Bleiziffer S, et al. Outcomes of transcatheter mitral valve replacement for degenerated bioprostheses, failed annuloplasty rings, and mitral annular calcification. Eur Heart J 2019; 40(5): 441-51. doi: 10.1093/eurheartj/ehy590 PMID: 30357365
  70. Hensey M, Brown RA, Lal S, et al. Transcatheter mitral valve replacement. JACC Cardiovasc Interv 2021; 14(5): 489-500. doi: 10.1016/j.jcin.2020.12.038 PMID: 33663778
  71. Yoon SH, Bleiziffer S, Latib A, et al. Predictors of left ventricular outflow tract obstruction after transcatheter mitral valve replacement. JACC Cardiovasc Interv 2019; 12(2): 182-93. doi: 10.1016/j.jcin.2018.12.001 PMID: 30678797
  72. Webb J, Hensey M, Fam N, et al. Transcatheter mitral valve replacement with the transseptal EVOQUE system. JACC Cardiovasc Interv 2020; 13(20): 2418-26. doi: 10.1016/j.jcin.2020.06.040 PMID: 33092713
  73. Benfari G, Antoine C, Miller WL, et al. Excess mortality associated with functional tricuspid regurgitation complicating heart failure with reduced ejection fraction. Circulation 2019; 140(3): 196-206. doi: 10.1161/CIRCULATIONAHA.118.038946 PMID: 31117814
  74. Kilic A, Saha-Chaudhuri P, Rankin JS, Conte JV. Trends and outcomes of tricuspid valve surgery in North America: An analysis of more than 50,000 patients from the Society of Thoracic Surgeons database. Ann Thorac Surg 2013; 96(5): 1546-52. doi: 10.1016/j.athoracsur.2013.06.031 PMID: 24070702
  75. Mesnier J, Alperi A, Panagides V, et al. Transcatheter tricuspid valve interventions: Current devices and associated evidence. Prog Cardiovasc Dis 2021; 69: 89-100. doi: 10.1016/j.pcad.2021.11.007 PMID: 34801577
  76. Taramasso M, Benfari G, van der Bijl P, et al. Transcatheter versus medical treatment of patients with symptomatic severe tricuspid regurgitation. J Am Coll Cardiol 2019; 74(24): 2998-3008. doi: 10.1016/j.jacc.2019.09.028 PMID: 31568868
  77. Lurz P, Stephan von Bardeleben R, Weber M, et al. Transcatheter edge-to-edge repair for treatment of tricuspid regurgitation. J Am Coll Cardiol 2021; 77(3): 229-39. doi: 10.1016/j.jacc.2020.11.038 PMID: 33478646
  78. Lurz P, Besler C, Schmitz T, et al. Short-term outcomes of tricuspid edge-to-edge repair in clinical practice. J Am Coll Cardiol 2023; 82(4): 281-91. doi: 10.1016/j.jacc.2023.05.008 PMID: 37207923
  79. Kodali S, Hahn RT, Eleid MF, et al. Feasibility study of the transcatheter valve repair system for severe tricuspid regurgitation. J Am Coll Cardiol 2021; 77(4): 345-56. doi: 10.1016/j.jacc.2020.11.047 PMID: 33509390
  80. Alperi A, Almendárez M, Álvarez R, et al. Transcatheter tricuspid valve interventions: Current status and future perspectives. Front Cardiovasc Med 2022; 9: 994502. doi: 10.3389/fcvm.2022.994502 PMID: 36187002
  81. Abdul-Jawad Altisent O, Benetis R, Rumbinaite E, et al. Caval valve implantation (CAVI): An emerging therapy for treating severe tricuspid regurgitation. J Clin Med 2021; 10(19): 4601. doi: 10.3390/jcm10194601 PMID: 34640619
  82. Lauten A, Dreger H, Laule M, Stangl K, Figulla HR, Eng MH. Caval valve implantation. Interv Cardiol Clin 2022; 11(1): 95-102. PMID: 34838301
  83. Estévez-Loureiro R, Sánchez-Recalde A, Amat-Santos IJ, et al. 6- month outcomes of the tricvalve system in patients with tricuspid regurgitation. JACC Cardiovasc Interv 2022; 15(13): 1366-77. doi: 10.1016/j.jcin.2022.05.022 PMID: 35583363
  84. Dreger H, Mattig I, Hewing B, et al. Treatment of severe tricuspid regurgitation in patients with advanced heart failure with caval vein implantation of the edwards sapien xt valve (TRICAVAL): A randomised controlled trial. EuroIntervention 2020; 15(17): 1506-13. doi: 10.4244/EIJ-D-19-00901 PMID: 31929100
  85. Nickenig G, Friedrichs KP, Baldus S, et al. Thirty-day outcomes of the cardioband tricuspid system for patients with symptomatic functional tricuspid regurgitation: The TriBAND study. EuroIntervention 2021; 17(10): 809-17. doi: 10.4244/EIJ-D-21-00300 PMID: 34031021
  86. Radhoe SP, Veenis JF, Brugts JJ. Invasive devices and sensors for remote care of heart failure patients. Sensors 2021; 21(6): 2014. doi: 10.3390/s21062014 PMID: 33809205
  87. Bourge RC, Abraham WT, Adamson PB, et al. Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: The COMPASS-HF study. J Am Coll Cardiol 2008; 51(11): 1073-9. doi: 10.1016/j.jacc.2007.10.061 PMID: 18342224
  88. Adamson PB, Gold MR, Bennett T, et al. Continuous hemodynamic monitoring in patients with mild to moderate heart failure: Results of the reducing decompensation events utilizing intracardiac pressures in patients with chronic heart failure (REDUCEhf) trial. Congest Heart Fail 2011; 17(5): 248-54. doi: 10.1111/j.1751-7133.2011.00247.x PMID: 21906250
  89. Abraham WT, Adamson PB, Bourge RC, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: A randomised controlled trial. Lancet 2011; 377(9766): 658-66. doi: 10.1016/S0140-6736(11)60101-3 PMID: 21315441
  90. Abraham WT, Adamson PB, Costanzo MR, et al. Hemodynamic monitoring in advanced heart failure: Results from the LAPTOP-HF trial. J Card Fail 2016; 22(11): 940. doi: 10.1016/j.cardfail.2016.09.012
  91. Udelson JE, Barker CM, Meduri C, et al. Six month results from first in human clinical experience of a no-implant interatrial shunt for heart failure with preserved ejection fraction. J Am Coll Cardiol 2022; 79(9) (Suppl.): 229-9. doi: 10.1016/S0735-1097(22)01220-7
  92. Rod és CJ, Bernier M, Amat -Santos Ignacio J, et al. Interatrial shunting for heart failure. JACC Cardiovasc Interv 2018; 11(2): 2300-10.
  93. Kaye DM, Nanayakkara S. Interatrial shunt device for heart failure with preserved ejection fraction. Front Cardiovasc Med 2019; 6: 143. doi: 10.3389/fcvm.2019.00143 PMID: 31620452
  94. Yi T, Li M, Fan F, et al. Haemodynamic changes of interatrial shunting devices for heart failure: A systematic review and meta-analysis. ESC Heart Fail 2022; 9(3): 1987-95. doi: 10.1002/ehf2.13911 PMID: 35322588
  95. Feldman T, Mauri L, Kahwash R, et al. Transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction (REDUCE LAP-HF I reduce elevated left atrial pressure in patients with heart failure). Circulation 2018; 137(4): 364-75. doi: 10.1161/CIRCULATIONAHA.117.032094 PMID: 29142012
  96. Shah SJ, Borlaug BA, Chung ES, et al. Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): A randomised, multicentre, blinded, sham-controlled trial. Lancet 2022; 399(10330): 1130-40. doi: 10.1016/S0140-6736(22)00016-2 PMID: 35120593
  97. Adhyapak SM, Parachuri VR. Architecture of the left ventricle: Insights for optimal surgical ventricular restoration. Heart Fail Rev 2010; 15(1): 73-83. doi: 10.1007/s10741-009-9151-0 PMID: 19757029
  98. Rangaswami J, Bhalla V, Blair JEA, et al. Cardiorenal syndrome: Classification, pathophysiology, diagnosis, and treatment strategies: A scientific statement from the american heart association. Circulation 2019; 139(16): e840-78. doi: 10.1161/CIR.0000000000000664 PMID: 30852913
  99. Mullens W, Abrahams Z, Francis GS, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 2009; 53(7): 589-96. doi: 10.1016/j.jacc.2008.05.068 PMID: 19215833
  100. Nijst P, Martens P, Dupont M, Tang WHW, Mullens W. Intrarenal flow alterations during transition from euvolemia to intravascular volume expansion in heart failure patients. JACC Heart Fail 2017; 5(9): 672-81. doi: 10.1016/j.jchf.2017.05.006 PMID: 28711449
  101. Vora AN, Schuyler Jones W, DeVore AD, Ebner A, Clifton W, Patel MR. First-in-human experience with Aortix intraaortic pump. Catheter Cardiovasc Interv 2019; 93(3): 428-33. doi: 10.1002/ccd.27857 PMID: 30311400
  102. Zymliński R, Dierckx R, Biegus J, Vanderheyden M, Bartunek J, Ponikowski P. Novel IVC doraya catheter provides congestion relief in patients with acute heart failure. JACC Basic Transl Sci 2022; 7(3): 326-7. doi: 10.1016/j.jacbts.2022.02.013 PMID: 35411326
  103. Maron MS, Olivotto I, Betocchi S, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003; 348(4): 295-303. doi: 10.1056/NEJMoa021332 PMID: 12540642
  104. Maron MS, Ommen SR. Exploring new and old therapies for obstructive hypertrophic cardiomyopathy. Circulation 2021; 143(12): 1181-3. doi: 10.1161/CIRCULATIONAHA.120.051330 PMID: 33750209
  105. Zhou M, Ta S, Hahn RT, et al. Percutaneous intramyocardial septal radiofrequency ablation in patients with drug-refractory hypertrophic obstructive cardiomyopathy. JAMA Cardiol 2022; 7(5): 529-38. doi: 10.1001/jamacardio.2022.0259 PMID: 35353129
  106. Khan JM, Bruce CG, Greenbaum AB, et al. Transcatheter myotomy to relieve left ventricular outflow tract obstruction: The septal scoring along the midline endocardium procedure in animals. Circ Cardiovasc Interv 2022; 15(6): e011686. doi: 10.1161/CIRCINTERVENTIONS.121.011686 PMID: 35378990

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML

© Bentham Science Publishers, 2024